氨酚羟考酮的临床应用进展
Clinical Application Progress of Acetaminophen Oxycodone
DOI: 10.12677/acm.2025.15123653, PDF,   
作者: 王 佳, 马淑敏, 王胜军：包头医学院赤峰学院附属医院疼痛科，内蒙古 赤峰
关键词: 氨酚羟考酮；临床应用；镇痛；Paracetamol Oxycodone； Clinical Application； Analgesia
摘要: 氨酚羟考酮是临床上常用的镇痛药物，核心成分是由阿片类生物碱的半合成蒂巴因衍生物–羟考酮5 mg及对乙酰氨基酚325 mg联合组成的复方制剂，于20世纪70年代首次在美国获批上市，羟考酮与对乙酰氨基酚的作用机制不同，二者联用可从不同的通路阻断疼痛信号，实现“1 + 1 > 2”的镇痛效果，最初用于术后疼痛、创伤性疼痛等中重度急性疼痛的短期治疗，因其明确的镇痛效果现已在临床疼痛管理方面应用广泛。本文旨在对氨酚羟考酮的药效学、药代学、临床应用及其不良反应进行梳理，以期为临床实践提供参考。
Abstract: Oxycodone and acetaminophen is a commonly used analgesic in clinical practice. Its core components are a semi-synthetic codeine derivative-oxycodone 5 mg and acetaminophen 325 mg, which were first approved for marketing in the United States in the 1970s. The mechanisms of action of oxycodone and acetaminophen are different. Their combination can block pain signals through different pathways, achieving an analgesic effect of “1 + 1 > 2”. It was initially used for short-term treatment of moderate to severe acute pain, such as postoperative pain and traumatic pain. Due to its clear analgesic effect, it is now widely used in clinical pain management. This article aims to review the pharmacodynamics, pharmacokinetics, clinical applications, and adverse reactions of oxycodone and acetaminophen, with the aim of providing a reference for clinical practice.
文章引用：王佳, 马淑敏, 王胜军. 氨酚羟考酮的临床应用进展[J]. 临床医学进展, 2025, 15(12): 2271-2283. https://doi.org/10.12677/acm.2025.15123653

参考文献

[1] Barrett, J.E., Shekarabi, A. and Inan, S. (2023) Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. Pharmacological Reviews, 75, 1062-1118. [Google Scholar] [CrossRef] [PubMed]
[2] 郭伟兵, 李文君, 段姣, 等. 羟考酮与吗啡在大鼠内脏痛镇痛效应的差异[J]. 东南国防医药, 2018, 20(4): 365-370.
[3] Proft, J. and Weiss, N. (2015) G Protein Regulation of Neuronal Calcium Channels: Back to the Future. Molecular Pharmacology, 87, 890-906. [Google Scholar] [CrossRef] [PubMed]
[4] Kuo, A., Magiera, J., Rethwan, N., Andersson, Å., Leen Lam, A., Wyse, B., et al. (2020) In Vitro Profiling of Opioid Ligands Using the Camp Formation Inhibition Assay and the β-Arrestin2 Recruitment Assay: No Two Ligands Have the Same Profile. European Journal of Pharmacology, 872, Article ID: 172947. [Google Scholar] [CrossRef] [PubMed]
[5] Berecki, G., Motin, L. and Adams, D.J. (2016) Voltage-Gated R-Type Calcium Channel Inhibition via Human μ-, δ-, and Κ-Opioid Receptors Is Voltage-Independently Mediated by Gβγ Protein Subunits. Molecular Pharmacology, 89, 187-196. [Google Scholar] [CrossRef] [PubMed]
[6] Weiss, N. and Zamponi, G.W. (2020) Opioid Receptor Regulation of Neuronal Voltage-Gated Calcium Channels. Cellular and Molecular Neurobiology, 41, 839-847. [Google Scholar] [CrossRef] [PubMed]
[7] Ozdemir, E. (2017) The Pathophysiological Role of Serotonin Receptor Systems in Opioid Analgesia and Tolerance. International Journal of Basic & Clinical Pharmacology, 6, 217-228. [Google Scholar] [CrossRef] 
[8] Tavares, I., Costa-Pereira, J.T. and Martins, I. (2021) Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights into the Clinical Challenges of Pain Treatment? Frontiers in Pain Research, 2, Article 696515. [Google Scholar] [CrossRef] [PubMed]
[9] Clissold, S.P. (1986) Paracetamol and Phenacetin. Drugs, 32, 46-59. [Google Scholar] [CrossRef] [PubMed]
[10] Prescott, L. (1980) Kinetics and Metabolism of Paracetamol and Phenacetin. British Journal of Clinical Pharmacology, 10, 291S-298S. [Google Scholar] [CrossRef] [PubMed]
[11] McGill, M.R. and Jaeschke, H. (2013) Metabolism and Disposition of Acetaminophen: Recent Advances in Relation to Hepatotoxicity and Diagnosis. Pharmaceutical Research, 30, 2174-2187. [Google Scholar] [CrossRef] [PubMed]
[12] Mallet, C., Barrière, D.A., Ermund, A., Jönsson, B.A.G., Eschalier, A., Zygmunt, P.M., et al. (2010) TRPV1 in Brain Is Involved in Acetaminophen-Induced Antinociception. PLOS ONE, 5, e12748. [Google Scholar] [CrossRef] [PubMed]
[13] Dalmann, R., Daulhac, L., Antri, M., Eschalier, A. and Mallet, C. (2015) Supra-Spinal FAAH Is Required for the Analgesic Action of Paracetamol in an Inflammatory Context. Neuropharmacology, 91, 63-70. [Google Scholar] [CrossRef] [PubMed]
[14] Mallet, C., Desmeules, J., Pegahi, R. and Eschalier, A. (2023) An Updated Review on the Metabolite (am404)-Mediated Central Mechanism of Action of Paracetamol (acetaminophen): Experimental Evidence and Potential Clinical Impact. Journal of Pain Research, 16, 1081-1094. [Google Scholar] [CrossRef] [PubMed]
[15] Dvorakova, M., Bosquez-Berger, T., Billingsley, J., Murataeva, N., Woodward, T., Leishman, E., et al. (2025) Acetaminophen Inhibits Diacylglycerol Lipase Synthesis of 2-Arachidonoyl Glycerol: Implications for Nociception. Cell Reports Medicine, 6, Article ID: 102139. [Google Scholar] [CrossRef] [PubMed]
[16] 徐建国. 盐酸羟考酮的药理学和临床应用[J]. 临床麻醉学杂志, 2014, 30(5): 511-513.
[17] Olkkola, K.T., Kontinen, V.K., Saari, T.I. and Kalso, E.A. (2013) Does the Pharmacology of Oxycodone Justify Its Increasing Use as an Analgesic? Trends in Pharmacological Sciences, 34, 206-214. [Google Scholar] [CrossRef] [PubMed]
[18] Doyle, M.R., Martinez, A.R., Qiao, R., Dirik, S., Di Ottavio, F., Pascasio, G., et al. (2023) Strain and Sex-Related Behavioral Variability of Oxycodone Dependence in Rats. Neuropharmacology, 237, Article ID: 109635. [Google Scholar] [CrossRef] [PubMed]
[19] Arguelles, N., Miksys, S. and Tyndale, R.F. (2021) Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels. Molecular Neurobiology, 58, 6540-6551. [Google Scholar] [CrossRef] [PubMed]
[20] Ballester, P., Muriel, J. and Peiró, A.M. (2022) CYP2D6 Phenotypes and Opioid Metabolism: The Path to Personalized Analgesia. Expert Opinion on Drug Metabolism & Toxicology, 18, 261-275. [Google Scholar] [CrossRef] [PubMed]
[21] Pednekar, D., Russell, J., Bardolia, C., Thacker, D. and Amin, N.S. (2024) Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone. The Senior Care Pharmacist, 39, 137-142. [Google Scholar] [CrossRef] [PubMed]
[22] Samer, C., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C., Rebsamen, M., et al. (2010) Genetic Polymorphisms and Drug Interactions Modulating CYP2D6 and CYP3A Activities Have a Major Effect on Oxycodone Analgesic Efficacy and Safety. British Journal of Pharmacology, 160, 919-930. [Google Scholar] [CrossRef] [PubMed]
[23] Andreassen, T.N., Eftedal, I., Klepstad, P., Davies, A., Bjordal, K., Lundström, S., et al. (2011) Do CYP2D6 Genotypes Reflect Oxycodone Requirements for Cancer Patients Treated for Cancer Pain? A Cross-Sectional Multicentre Study. European Journal of Clinical Pharmacology, 68, 55-64. [Google Scholar] [CrossRef] [PubMed]
[24] Caparrotta, T.M., Antoine, D.J. and Dear, J.W. (2017) Are Some People at Increased Risk of Paracetamol-Induced Liver Injury? A Critical Review of the Literature. European Journal of Clinical Pharmacology, 74, 147-160. [Google Scholar] [CrossRef] [PubMed]
[25] 王帆, 朱哿瑞, 刘成海, 等. 对乙酰氨基酚致药物性肝损伤的分子机制[J]. 肝脏, 2021, 26(8): 939-942.
[26] 中华人民共和国国家卫生健康委员会. 癌症疼痛诊疗规范(2018年版) [J]. 临床肿瘤学杂志, 2018, 23(10): 937-944.
[27] Mazaleuskaya, L.L., Sangkuhl, K., Thorn, C.F., FitzGerald, G.A., Altman, R.B. and Klein, T.E. (2015) PharmGKB Summary: Pathways of Acetaminophen Metabolism at the Therapeutic versus Toxic Doses. Pharmacogenetics and Genomics, 25, 416-426. [Google Scholar] [CrossRef] [PubMed]
[28] 中国神经病理性疼痛诊疗指南制订专家组, 中国老年保健协会疼痛病学分会, 程志祥, 等. 中国神经病理性疼痛诊疗指南(2024版) [J]. 中华疼痛学杂志, 2024, 20(4): 484-508.
[29] 国家疼痛专业质控中心神经病理性疼痛专家组, 段宝霖, 樊碧发, 等. 神经病理性疼痛评估与管理中国指南(2024版) [J]. 中国疼痛医学杂志, 2024, 30(1): 5-14.
[30] 中国医师协会皮肤科医师分会带状疱疹专家共识工作组, 国家皮肤与免疫疾病临床医学研究中心. 中国带状疱疹诊疗专家共识(2022版) [J]. 中华皮肤科杂志, 2022, 55(12): 1033-1040.
[31] 刘斌. 普瑞巴林联合氨酚羟考酮治疗带状疱疹后遗神经痛的临床疗效分析[J]. 健康必读, 2021, 26(26): 89-90.
[32] 骆丽, 方鸿. 氨酚羟考酮联合加巴喷丁治疗中老年带状疱疹疼痛的效果[J]. 皮肤病与性病, 2020, 42(3): 405-406.
[33] 兰培丽, 王瑾. 氨酚羟考酮联合加巴喷丁治疗中老年带状疱疹相关性疼痛的疗效[J]. 中国老年学杂志, 2013, 33(10): 2260-2262.
[34] 杜海峰, 张君. 氨酚羟考酮联合加巴喷丁治疗中老年带状疱疹相关性疼痛的效果[J]. 中国实用医刊, 2019, 46(4): 105-108.
[35] 查曹兵, 孙德弢. 加巴喷丁联合氨酚羟考酮治疗老年糖尿病周围神经痛效果观察[J]. 中国乡村医药, 2015(16): 14-15.
[36] 李书娟. 加巴喷丁胶囊联合氨酚羟考酮片治疗老年糖尿病周围神经痛的疗效观察[J]. 国际医药卫生导报, 2016, 22(7): 981-983.
[37] Kinnunen, M., Piirainen, P., Kokki, H., Lammi, P. and Kokki, M. (2019) Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone. Clinical Pharmacokinetics, 58, 705-725. [Google Scholar] [CrossRef] [PubMed]
[38] 张津铭, 李兴艳, 叶亚平, 等. 氨酚羟考酮联合普瑞巴林治疗腰椎间盘突出症155例[J]. 医药导报, 2015, 34(2): 177-180.
[39] 周宁, 马岭. 马来酸氟吡汀对原发性三叉神经痛临床治疗效果的影响分析[J]. 中国医学前沿杂志(电子版), 2016, 8(11): 101-104.
[40] 万复甦. 低剂量氨酚羟考酮片与可待因治疗中度骨转移癌痛的随机对照研究[J]. 肿瘤防治研究, 2019, 46(7): 634-637.
[41] 张新宇. 盐酸羟考酮缓控释片治疗中重度癌痛的安全性和有效性系统评价[J]. 中国医院药学杂志, 2024, 44(8): 891-895.
[42] 石明宏. 氨酚羟考酮联合局部放疗对老年恶性肿瘤骨转移癌痛患者血清细胞因子的影响[J]. 实用医学杂志, 2025, 41(11): 1890-1893.
[43] 张蕾. 氨酚羟考酮片与盐酸吗啡片对高龄阿片类药物耐受癌痛患者暴发痛及血清炎症因子的影响[J]. 转化医学杂志, 2025, 14(6): 345-349.
[44] 伍静. 氨酚羟考酮治疗晚期肺癌骨转移患者爆发性疼痛的疗效及对疼痛介质水平的影响[J]. 癌症进展, 2023, 21(11): 1234-1237.
[45] 杨寅, 柏龙文, 张延平. 氨酚羟考酮片用于膝关节骨性关节炎严重疼痛的治疗观察[J]. 中国新药杂志, 2009, 18(7): 626-627.
[46] 印卫锋, 陈苏, 熊伟, 等. 氨酚羟考酮片联合超短波治疗肩关节周围炎75例[J]. 医药导报, 2010, 29(2): 194-196.
[47] Martinez, V., Lehman, T., Lavand’homme, P., Harkouk, H., Kalso, E., Pogatzki-Zahn, E.M., et al. (2024) Chronic Postsurgical Pain. European Journal of Anaesthesiology, 41, 351-362. [Google Scholar] [CrossRef] [PubMed]
[48] Huang, A., Katz, J. and Clarke, H. (2015) Ensuring Safe Prescribing of Controlled Substances for Pain Following Surgery by Developing a Transitional Pain Service. Pain Management, 5, 97-105. [Google Scholar] [CrossRef] [PubMed]
[49] 刘晨阳, 赵世林, 杨婕, 等. 梅花针叩刺联合氨酚羟考酮治疗肺癌术后慢性疼痛的效果观察[J]. 癌症进展, 2021, 19(6): 570-574.
[50] 苗峰. 氨酚羟考酮在腰椎后路融合术后的镇痛效果观察[J]. 中国药房, 2017, 28(11): 1526-1528.
[51] Liu, J., Di, J., Zhang, Y. and Xing, E. (2021) Oxycodone-Paracetamol Tablet Exhibits Increased Analgesic Efficacy for Acute Postoperative Pain, Higher Satisfaction and Comparable Safety Profiles Compared with Celecoxib in Patients Underwent Arthroscopic Knee Surgery. Inflammopharmacology, 29, 1091-1099. [Google Scholar] [CrossRef] [PubMed]
[52] Zareian Baghdadabad, L., Mohammadi, A., Menbari Oskouie, I., Alaeddini, F., Farajidavar, H., Oliveira Reis, L., et al. (2025) Evaluation of the Analgesic Effect of a Combination of Oral Acetaminophen and Oxycodone after Extracorporeal Shock Wave Lithotripsy (SWL). Urologia Journal, 92, 439-445. [Google Scholar] [CrossRef] [PubMed]
[53] 唐英. 氨酚羟考酮在髋关节置换术超前镇痛中的应用效果及安全性[J]. 临床合理用药, 2025, 18(14): 56-58.
[54] Zhang, J., Tu, Q., Gan, J., Miao, S., Zhou, Y., Li, Q., et al. (2019) Preemptive Anti-Stress Response Effects of Oxycodone versus Sufentanil for Patients Undergoing Cardiac Valve Replacement—A Randomized Controlled Trial. Clinical Pharmacology in Drug Development, 9, 321-329. [Google Scholar] [CrossRef] [PubMed]
[55] 周庆明, 樊碧发, 潘海鹏, 等. 腰穿联合氨酚羟考酮治疗创伤后头痛的临床研究[J]. 中国疼痛医学杂志, 2013, 19(4): 244-246.
[56] 李连华, 孙天胜, 刘智, 等. 氨酚羟考酮片平衡镇痛在急诊创伤患者中的应用[J]. 中国新药杂志, 2010, 19(23): 2161-2164.
[57] 刘锐克, 孙桂宽, 穆悦, 等. 可待因及羟考酮、右丙氧芬复方制剂依赖性的流行病学调查[J]. 中国药物依赖性杂志, 2004, 13(3): 213-217.
[58] Volkow, N.D. and McLellan, A.T. (2016) Opioid Abuse in Chronic Pain—Misconceptions and Mitigation Strategies. New England Journal of Medicine, 374, 1253-1263. [Google Scholar] [CrossRef] [PubMed]
[59] 徐杰, 等. 207例泰勒宁药物成瘾者临床分析报告[J]. 中国药物依赖性杂志, 2019, 28(5): 342-345
[60] 美国食品药品监督管理局(FDA). 阿片类镇痛药风险评估与减缓策略(Opioid Analgesic REMS) [EB/OL].
https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems, 2025-03-31.
[61] Dowell, D., Ragan, K.R., Jones, C.M., Baldwin, G.T. and Chou, R. (2022) CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. MMWR. Recommendations and Reports, 71, 1-95. [Google Scholar] [CrossRef] [PubMed]
[62] Busse, J.W., Craigie, S., Juurlink, D.N., Buckley, D.N., Wang, L., Couban, R.J., et al. (2017) Guideline for Opioid Therapy and Chronic Noncancer Pain. Canadian Medical Association Journal, 189, E659-E666. [Google Scholar] [CrossRef] [PubMed]
[63] 国务院. 麻醉药品和精神药品管理条例(2024修订): 中华人民共和国国务院令[2024]第797号[A/OL].
https://www.gov.cn/gongbao/2025/issue_11786/202501/content_6997034.html, 2024-12-06.
[64] Mary Hanna Bekhit, M. (2015) Profile of Extended-Release Oxycodone/acetaminophen for Acute Pain. Journal of Pain Research, 8, 719-728. [Google Scholar] [CrossRef] [PubMed]
[65] Petrò, E., Ruffini, E., Cappuccio, M., Guerini, V., Belotti, G., Fascendini, S., et al. (2016) Low-Dose Oral Prolonged-Release Oxycodone/Naloxone for Chronic Pain in Elderly Patients with Cognitive Impairment: An Efficacy-Tolerability Pilot Study. Neuropsychiatric Disease and Treatment, 12, 559-569. [Google Scholar] [CrossRef] [PubMed]
[66] Reimers, A., Odin, P. and Ljung, H. (2024) Drug-Induced Cognitive Impairment. Drug Safety, 48, 339-361. [Google Scholar] [CrossRef] [PubMed]
[67] 潘雪芬, 陈志民, 艾建国. 氨酚羟考酮对1435例住院患者肝功能的影响[J]. 药物流行病学杂志, 2019, 28(2): 114-117.

为你推荐